Cancer immunotherapy comes of age

被引：3489

作者：

Mellman, Ira ^{[1
]}

Coukos, George ^{[2
]}

Dranoff, Glenn ^{[3
,4
,5
]}

机构：

[1] Genentech Inc, San Francisco, CA 94080 USA

[2] Univ Penn, Sch Med, Ovarian Canc Res Ctr, Philadelphia, PA 19104 USA

[3] Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[4] Brigham & Womens Hosp, Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA

[5] Harvard Univ, Sch Med, Boston, MA 02115 USA

来源：

NATURE | 2011年 / 480卷 / 7378期

关键词：

REGULATORY T-CELLS; ENDOTHELIAL GROWTH-FACTOR; COLONY-STIMULATING FACTOR; DENDRITIC CELLS; ANTITUMOR IMMUNITY; PEPTIDE VACCINE; IN-VITRO; TUMOR; TOLERANCE; ANTIBODY;

D O I：

10.1038/nature10673

中图分类号：

O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];

学科分类号：

070301 [无机化学]; 070403 [天体物理学]; 070507 [自然资源与国土空间规划学]; 090105 [作物生产系统与生态工程];

摘要：

Activating the immune system for therapeutic benefit in cancer has long been a goal in immunology and oncology. After decades of disappointment, the tide has finally changed due to the success of recent proof-of-concept clinical trials. Most notable has been the ability of the anti-CTLA4 antibody, ipilimumab, to achieve a significant increase in survival for patients with metastatic melanoma, for which conventional therapies have failed. In the context of advances in the understanding of how tolerance, immunity and immunosuppression regulate antitumour immune responses together with the advent of targeted therapies, these successes suggest that active immunotherapy represents a path to obtain a durable and long-lasting response in cancer patients.

引用

页码：480 / 489

页数：10

共 99 条

[1]

Human mesenchymal stem cells modulate allogeneic immune cell responses [J].

Aggarwal, S ;

Pittenger, MF .

BLOOD, 2005, 105 (04) :1815-1822

[2]

Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemoimmunotherapy [J].

Alagkiozidis, Ioannis ;

Facciabene, Andrea ;

Tsiatas, Marinos ;

Carpenito, Carmine ;

Benencia, Fabian ;

Adams, Sarah ;

Jonak, Zdenka ;

June, Carl H. ;

Powell, Daniel J., Jr. ;

Coukos, George .

JOURNAL OF TRANSLATIONAL MEDICINE, 2011, 9

[3]

CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans [J].

Beatty, Gregory L. ;

Chiorean, Elena G. ;

Fishman, Matthew P. ;

Saboury, Babak ;

Teitelbaum, Ursina R. ;

Sun, Weijing ;

Huhn, Richard D. ;

Song, Wenru ;

Li, Dongguang ;

Sharp, Leslie L. ;

Torigian, Drew A. ;

O'Dwyer, Peter J. ;

Vonderheide, Robert H. .

SCIENCE, 2011, 331 (6024) :1612-1616

[4]

Human T cell responses against melanoma [J].

Boon, Thierry ;

Coulie, Pierre G. ;

Van den Eynde, Benoit J. ;

van der Bruggen, Pierre .

ANNUAL REVIEW OF IMMUNOLOGY, 2006, 24 :175-208

[5]

Effects of vascular endothelial growth factor on the lymphocyte-endothelium interactions: Identification of caveolin-1 and nitric oxide as control points of endothelial cell anergy [J].

Bouzin, Caroline ;

Brouet, Agnes ;

De Vriese, Joelle ;

DeWever, Julie ;

Feron, Olivier .

JOURNAL OF IMMUNOLOGY, 2007, 178 (03) :1505-1511

[6]

Phase I Study of Single-Agent Anti-Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates [J].

Brahmer, Julie R. ;

Drake, Charles G. ;

Wollner, Ira ;

Powderly, John D. ;

Picus, Joel ;

Sharfman, William H. ;

Stankevich, Elizabeth ;

Pons, Alice ;

Salay, Theresa M. ;

McMiller, Tracee L. ;

Gilson, Marta M. ;

Wang, Changyu ;

Selby, Mark ;

Taube, Janis M. ;

Anders, Robert ;

Chen, Lieping ;

Korman, Alan J. ;

Pardoll, Drew M. ;

Lowy, Israel ;

Topalian, Suzanne L. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (19) :3167-3175

[7]

Endothelin B receptor mediates the endothelial barrier to T cell homing to tumors and disables immune therapy [J].

Buckanovich, Ronald J. ;

Facciabene, Andrea ;

Kim, Sarah ;

Benencia, Fabian ;

Sasaroli, Dimitra ;

Balint, Klara ;

Katsaros, Dionysios ;

O'Brien-Jenkins, Anne ;

Gimotty, Phyllis A. ;

Coukos, George .

NATURE MEDICINE, 2008, 14 (01) :28-36

[8]

CTLA-4-mediated inhibition in regulation of T cell responses: Mechanisms and manipulation in tumor immunotherapy [J].

Chambers, CA ;

Kuhns, MS ;

Egen, JG ;

Allison, JP .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :565-594

[9]

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation [J].

Chapman, Paul B. ;

Hauschild, Axel ;

Robert, Caroline ;

Haanen, John B. ;

Ascierto, Paolo ;

Larkin, James ;

Dummer, Reinhard ;

Garbe, Claus ;

Testori, Alessandro ;

Maio, Michele ;

Hogg, David ;

Lorigan, Paul ;

Lebbe, Celeste ;

Jouary, Thomas ;

Schadendorf, Dirk ;

Ribas, Antoni ;

O'Day, Steven J. ;

Sosman, Jeffrey A. ;

Kirkwood, John M. ;

Eggermont, Alexander M. M. ;

Dreno, Brigitte ;

Nolop, Keith ;

Li, Jiang ;

Nelson, Betty ;

Hou, Jeannie ;

Lee, Richard J. ;

Flaherty, Keith T. ;

McArthur, Grant A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2011, 364 (26) :2507-2516

[10]

Translational research working group developmental pathway for immune response modifiers [J].

Cheever, Martin A. ;

Schlom, Jeffrey ;

Weiner, Louis M. ;

Lyerly, H. Kim ;

Disis, Mary L. ;

Greenwood, Addison ;

Grad, Oren ;

Nelson, William G. .

CLINICAL CANCER RESEARCH, 2008, 14 (18) :5692-5699

← 1 2 3 4 5 6 7 8 9 10 →